NEW YORK (GenomeWeb News) — Transgenomic today said that Italian molecular diagnostic shop Fiuotecnica will use its Wave technology to develop and market a genetic assay panel to predict the risk of cardiovascular disease and heart attacks.
Fiuotecnica will retain rights to market the panel in Italy and Transgenomic will obtain rights to market it in the rest of the world.
Financial terms of the agreement were not disclosed.